BCR-ABL
Philadelphia chromosome fusion gene defining CML and Ph+ ALL. Targeted by imatinib, dasatinib, nilotinib, ponatinib, asciminib.
No Clinical Trials found for this biomarker.
Philadelphia chromosome fusion gene defining CML and Ph+ ALL. Targeted by imatinib, dasatinib, nilotinib, ponatinib, asciminib.
No Clinical Trials found for this biomarker.